Logo image of RLAY

RELAY THERAPEUTICS INC (RLAY) Stock Fundamental Analysis

NASDAQ:RLAY - Nasdaq - US75943R1023 - Common Stock - Currency: USD

3.08  +0.13 (+4.41%)

After market: 3.05 -0.03 (-0.97%)

Fundamental Rating

4

RLAY gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 560 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RLAY as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, RLAY is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RLAY had negative earnings in the past year.
RLAY had a negative operating cash flow in the past year.
RLAY had negative earnings in each of the past 5 years.
In the past 5 years RLAY always reported negative operating cash flow.
RLAY Yearly Net Income VS EBIT VS OCF VS FCFRLAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

RLAY has a Return On Assets (-38.76%) which is comparable to the rest of the industry.
With a decent Return On Equity value of -43.42%, RLAY is doing good in the industry, outperforming 68.57% of the companies in the same industry.
Industry RankSector Rank
ROA -38.76%
ROE -43.42%
ROIC N/A
ROA(3y)-35.23%
ROA(5y)-34.11%
ROE(3y)-39.82%
ROE(5y)-38.03%
ROIC(3y)N/A
ROIC(5y)N/A
RLAY Yearly ROA, ROE, ROICRLAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

RLAY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RLAY Yearly Profit, Operating, Gross MarginsRLAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

7

2. Health

2.1 Basic Checks

RLAY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RLAY has more shares outstanding
Compared to 5 years ago, RLAY has more shares outstanding
There is no outstanding debt for RLAY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RLAY Yearly Shares OutstandingRLAY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RLAY Yearly Total Debt VS Total AssetsRLAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

RLAY has an Altman-Z score of 0.10. This is a bad value and indicates that RLAY is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.10, RLAY is in the better half of the industry, outperforming 65.18% of the companies in the same industry.
There is no outstanding debt for RLAY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.1
ROIC/WACCN/A
WACC9.52%
RLAY Yearly LT Debt VS Equity VS FCFRLAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

RLAY has a Current Ratio of 15.95. This indicates that RLAY is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of RLAY (15.95) is better than 90.18% of its industry peers.
A Quick Ratio of 15.95 indicates that RLAY has no problem at all paying its short term obligations.
RLAY has a Quick ratio of 15.95. This is amongst the best in the industry. RLAY outperforms 90.18% of its industry peers.
Industry RankSector Rank
Current Ratio 15.95
Quick Ratio 15.95
RLAY Yearly Current Assets VS Current LiabilitesRLAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

RLAY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.53%, which is quite good.
The Revenue for RLAY has decreased by -60.83% in the past year. This is quite bad
The Revenue has been growing by 48.92% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)15.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
Revenue 1Y (TTM)-60.83%
Revenue growth 3Y48.92%
Revenue growth 5YN/A
Sales Q2Q%-23.26%

3.2 Future

RLAY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.38% yearly.
The Revenue is expected to grow by 83.83% on average over the next years. This is a very strong growth
EPS Next Y19.19%
EPS Next 2Y9.47%
EPS Next 3Y5.94%
EPS Next 5Y14.38%
Revenue Next Year-40.07%
Revenue Next 2Y27.02%
Revenue Next 3Y45.59%
Revenue Next 5Y83.83%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RLAY Yearly Revenue VS EstimatesRLAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
RLAY Yearly EPS VS EstimatesRLAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RLAY. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RLAY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RLAY Price Earnings VS Forward Price EarningsRLAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RLAY Per share dataRLAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.47%
EPS Next 3Y5.94%

More info and screens

0

5. Dividend

5.1 Amount

RLAY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RELAY THERAPEUTICS INC

NASDAQ:RLAY (5/29/2025, 8:11:17 PM)

After market: 3.05 -0.03 (-0.97%)

3.08

+0.13 (+4.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners82.86%
Inst Owner Change4.68%
Ins Owners1.92%
Ins Owner Change1.7%
Market Cap528.04M
Analysts84.21
Price Target17.34 (462.99%)
Short Float %14.1%
Short Ratio6.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.5%
Min EPS beat(2)19.53%
Max EPS beat(2)21.46%
EPS beat(4)4
Avg EPS beat(4)15.61%
Min EPS beat(4)7.69%
Max EPS beat(4)21.46%
EPS beat(8)7
Avg EPS beat(8)12.57%
EPS beat(12)9
Avg EPS beat(12)9.64%
EPS beat(16)10
Avg EPS beat(16)-14.85%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)3053.38%
Min Revenue beat(4)-100%
Max Revenue beat(4)12513.5%
Revenue beat(8)3
Avg Revenue beat(8)2332.03%
Revenue beat(12)4
Avg Revenue beat(12)1545.81%
Revenue beat(16)5
Avg Revenue beat(16)1175.79%
PT rev (1m)-14.57%
PT rev (3m)-20.93%
EPS NQ rev (1m)0%
EPS NQ rev (3m)19.34%
EPS NY rev (1m)8.88%
EPS NY rev (3m)28.19%
Revenue NQ rev (1m)-9.99%
Revenue NQ rev (3m)-80%
Revenue NY rev (1m)100.74%
Revenue NY rev (3m)164.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 52.77
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB 0.68
EV/EBITDA N/A
EPS(TTM)-2.23
EYN/A
EPS(NY)-1.92
Fwd EYN/A
FCF(TTM)-1.46
FCFYN/A
OCF(TTM)-1.45
OCFYN/A
SpS0.06
BVpS4.54
TBVpS4.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.76%
ROE -43.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.23%
ROA(5y)-34.11%
ROE(3y)-39.82%
ROE(5y)-38.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 36.93%
Cap/Sales 20.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.95
Quick Ratio 15.95
Altman-Z 0.1
F-Score3
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)111.54%
Cap/Depr(5y)95.45%
Cap/Sales(3y)230.95%
Cap/Sales(5y)161.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
EPS Next Y19.19%
EPS Next 2Y9.47%
EPS Next 3Y5.94%
EPS Next 5Y14.38%
Revenue 1Y (TTM)-60.83%
Revenue growth 3Y48.92%
Revenue growth 5YN/A
Sales Q2Q%-23.26%
Revenue Next Year-40.07%
Revenue Next 2Y27.02%
Revenue Next 3Y45.59%
Revenue Next 5Y83.83%
EBIT growth 1Y43.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.6%
EBIT Next 3Y3.6%
EBIT Next 5Y8.81%
FCF growth 1Y17.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.05%
OCF growth 3YN/A
OCF growth 5YN/A